ClinicalTrials.gg
CompletedNCT04888429CAPSTONEUpdated Oct 14, 2026

Camrelizumab Plus Famitinib as Treatment in Patient With Advanced or Metastatic Pulmonary Sarcomatoid Carcinoma

A Phase 2 interventional study of Camrelizumab and Famitinib in Sarcomatoid Carcinoma of Lung, sponsored by Qian Chu. Completed at 8 sites in China. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2026-10-14.

Sponsored by Qian Chu · Phase 2, Interventional, and Treatment

How we know

Updated Oct 14, 2026Now CompletedEnrollment updatedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
17
Allocation
Not applicable
Ages
18 Years to 75 Years
Sex
All
01

Study summary

This is a single arm, multi-center clinical trial. Target population is patients with Advanced or Metastatic Pulmonary Sarcomatoid Carcinoma,aiming to evaluate the efficacy and safety of the combination therapy of Camrelizumab and famitinib . Camrelizumab is a humanized anti-PD1 IgG4 monoclonal antibody, and famitinib is an orally bioavailable receptor tyrosine kinase (RTK) inhibitor.

Read the detailed description

This trial enrolled patients with advanced or metastatic pulmonary sarcomatoid carcinoma. Patients will receive camrelizumab 200 mg every 3 weeks and famitinib 20 mg once per day. The primary endpoint is objective response rate (ORR) assessed by investigators per RECIST version 1.1. Key secondary endpoints were progression-free survival (PFS), overall survival (OS), duration of response, and safety.

02

Conditions studied

  • Sarcomatoid Carcinoma of Lung

Keywords

  • Sarcomatoid Carcinoma of Lung
  • Camrelizumab
  • Famitinib
03

In context

Lead sponsor

Qian Chu is the lead sponsor of 7 studies on the registry; 4 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Patients with histologically stage IIIB, IIIC, IV Pulmonary Sarcomatoid Carcinoma according to WHO criteria or diagnosed with non-small cell lung cancer with sarcomatoid carcinoma component (sarcomatoid component tumour cells can be spindle cells, and/or giant cells and/or heterogenous sarcomatous differentiation including rhabdomyosarcoma, chondrosarcoma, etc.) ;
  • Has no prior systemic therapy; (chemotherapy and/or radiotherapy is allowed as part of /adjuvant therapy. Patients who have had recurrence or for more than 6 months from the end of neoadjuvant/adjuvant treatment would be enrolled ) ;
  • Patients must have at least one according to 1.1 ;
  • score 0-1 ;
  • Agree to provide tumour tissue samples for biomarker exploration (including but not limited to IHC or NGS testing) ;
  • more than 3 months;
  • Has adequate organ function;

Exclusion criteria

Exclusion Criteria:

  • Imaging (CT or MRI) showed tumor invasion of major vessels. hemoptysis ≥ 2.5 mL within 1 month before the first dose;
  • Patients with EGFR-sensitive mutation (19Exondel/L858R), ALK, ROS1 gene rearrangement or fusion, BRAFV600E mutation, MET gene exon 14 skipping mutation;
  • Patients with active bleeding or bleeding tendency ;
  • With hypertension that cannot be reduced to the normal range after antihypertensive drug treatment (systolic blood pressure ≤ 140 mmHg/diastolic blood pressure ≤ 90 mmHg);
  • Urine protein ≥ (+ +), and 24-hour urine protein ≥ 1.0g;
  • Presence of thrombotic disorder requiring anticoagulant therapy with warfarin or heparin, or requiring antiplatelet therapy (aspirin ≥ 300 mg/day or clopidogrel ≥ 75 mg/day) ;
  • Has multiple factors affecting the absorption of oral drugs, such as inability to swallow, nausea and vomiting, chronic diarrhea and intestinal obstruction
  • Has active central nervous system (CNS) confirmed by CT or MRI
  • Subjects diagnosed immunodeficiency or receiving systemic therapy or any other form of therapy of non-related tumor within 7 days before the first dose; allowed physiological dose of glucocorticoid (≤10 mg/day Prednisone or equivalent);
  • Has active ;
  • Has severe infections within 4 weeks of the first dose of study treatment ;
  • Women who are pregnant or lactating ;
  • With grade II or above myocardial ischemia or myocardial infarction and poorly controlled arrhythmias ( ≥ 450 ms for males and QTc interval ≥ 470 ms for females). Subjects with grade III-IV cardiac insufficiency or with (LVEF) less than 50% according to criteria;
  • Has known history of (HIV);
  • Has known allergy to Camrelizumab, or famitinib or any of accessories ;
Terms in these criteria, in plain language(14)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Adjuvant and neoadjuvant

Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

PD-1, PD-L1 and checkpoint inhibitors

PD-1, PD-L1 and CTLA-4 are proteins that act as brakes on the immune system. Checkpoint inhibitors, such as pembrolizumab or nivolumab, block them so the immune system can attack a cancer.

PD-L1 can also be measured in a tumor sample. Some scores count stained tumor cells only (TPS); others also count certain immune cells (CPS). The study names the score and the minimum it uses.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
17 participants (actual)

Study arms

  • Experimental
    Camrelizumab + Famitinib

    Patients received camrelizumab 200 mg every 3 weeks and famitinib 20 mg once per day.

    Drug: Camrelizumab · Drug: Famitinib

Interventions

  • Patients received camrelizumab 200 mg every 3 weeks

    Also known as: SHR-1210

  • Patients received Famitinib 20 mg once per day

    Also known as: SHR-1020

06

What researchers measure

Primary outcomes

  1. Objective Response Rate (ORR)

    Objective Response Rate using RECIST 1.1 criteria, Proportion of patients with CR and PR

    Time frame: about 24 month

Secondary outcomes

  1. Progression-free Survival

    Time from the date of first dose to first observation of progression (RECIST1.1) or date of death (from any cause)

    Time frame: about 24 month

  2. Overall Survival

    Time from the date of first dose to death from any cause

    Time frame: about 24 month

  3. Duration of response

    Time from the date of the first documented response (CR or PR) to the earliest date of disease progression (RECIST 1.1), or death due to any cause.

    Time frame: about 24 month

  4. incidence, type and severity of adverse events

    Descriptive statistics of safety will be presented using National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE), version 5.0

    Time frame: From time of informed consent through treatment period and up to 30 days post last dose of study treatment (about 24 months)

  5. Disease control rate

    Disease control rate using RECIST 1.1 criteria, Proportion of patients with CR, PR and SD

    Time frame: about 24 month

07

Study locations

8 sites
  • The first Affiliated Hospital of Xiamen University
    Xiamen, Fujian, China
  • Henan Cancer Hospital Affiliated Cancer Hospital of Zhengzhou University
    Zhengzhou, Henan, China
  • Henan Provincial People's Hospital
    Zhengzhou, Henan, China
  • Qian Chu
    Wuhan, Hubei 430000, China
  • Hubei Cancer Hospital
    Wuhan, Hubei, China
  • Renmin Hospital of Wuhan University Hubei General Hospital
    Wuhan, Hubei, China
  • The Second Xiangya Hospital of Central South University
    Changsha, Hunan, China
  • The First Affiliated Hospital of Shandong First Medical University
    Jinan, Shandong, China
08

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Jul 2021 to primary completion in Dec 2024, 41 months.

How these figures are worked out, and which studies are left out of them.

Registered
May 12, 2021
First posted
May 17, 2021
StartActual
Jul 19, 2021
Primary completionActual
Dec 30, 2024
CompletionActual
Jun 30, 2025
Last update
Oct 14, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Recruiting→Completed
changed Oct 14, 2026
Enrollment
28 (estimated)→17 (actual)
Oct 14, 2026
Show all 1 update
  1. Oct 14, 2026
    Recruiting→Completed
    Enrollment 28 (estimated)→17 (actual)
    + 5 other changes: verification date, date precision, contact details, site details and index terms

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

09

Registry details

Key details

Study ID
NCT04888429
Lead sponsor
Qian Chu
Responsible party
Qian Chu (Professor, Tongji Hospital) — Sponsor-investigator
First posted
May 17, 2021
Start date
Jul 19, 2021
Primary completion
Dec 30, 2024
Completion
Jun 30, 2025
Last update
Oct 14, 2026

Study contacts

Qian Chu
principal investigator · Tongji Hospital
Lin Wu
principal investigator · Hunan Cancer Hospital

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Camrelizumab · Famitinib

Start the discussion